Author: Psychedelic Spotlight

What’s up psychedelic investors! In this episode, we’ll be comparing the top 10 psychedelic stocks’ financials.
Will look at the 4 most important financial stats for each of the top 10 companies in the Psychedelic Medicines field, selected by market cap.

First, we will look at the market cap, because that tells us how valuable the market judges the company to be, and it tells us how easily a company can raise capital.
Next, we will look at cash on hand.
Third, we will look at how much a company is spending.
Finally, we will look at revenue where applicable
All figures are in American dollars.

So which stocks we’ll be comparing, you may ask? We’ll look at:
– Atai Life Sciences ( NASDAQ: ATAI)
– Compass Pathways (NASDAQ: CMPS)
-MindMed (NASDAQ: MNMD), ( NEO: MMED)
– Cybin Inc (NYSE: CYBN)
– Numinus Wellneass (TSX: NUMI) (OTC: LKYSF)
– Revive Therapeutics (CN: RVV) (OTC: RVVTF)
– Small Pharma ( TSX: DMT)
-Mydecine (OTC: MYCOF) (NEO: MYCO)
– Red Light Holland ( CSE: TRIP) (OTC: TRUFF)

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #ATAISTOCK #PsychedelicStocks

What are top 5 catalysts for psychedelic stocks in the second half of 2021? Stay tuned to hear how stocks like MindMed (NASDAQ: MNMD),
(NEO:MMED), Compass Pathways (NASDAQ: CMPS), atai Life Sciences ( NASDAQ: ATAI), Tryp Therapeutics, Cybin and more will affect the psychedelic industry in 2021.

Timestamps:

0:00 – Intro
1:38 – #5: A New Psychedelics ETF (PSIL)
4:57 – #4:California Decriminalizing possession of psychedelics, and Legalising the personal production of Psilocybin
7:30 – #3:The commencement of MANY phase 2a trials
10:16 – #2: MindMed’s Project Lucy phase 2b trial begins
11:47 – #1: Compass Pathways phase 2b trial results released

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Check out our website: thepsychedelicinvestor.com

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

#MindMed #MNMD #PsychedelicStocks

Check out atai Life Sciences’ earnings call: https://www.youtube.com/watch?v=lkE3EmU0o_w

What’s up psychedelic stocks investors?!? Today marked MindMed’s (MNMD /MMED) Second Quarter 2021 conference call. In the conference call, MindMed gave updates on their varying projects, such as treating anxiety with LSD, addiction with 18MC, and pain with LSD. They also give insights into their digital medicines division and gave an update on their hiring spree.

This Kevin O’Leary-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 17+ different projects under their belt, MindMed is one of the most exciting companies to keep an eye on in the industry.

This conference call can help investors answer the questions: is MNMD stock a good investment? Will MMED go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Check out our website: thepsychedelicinvestor.com

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

#MindMed #MNMD #PsychedelicStocks

What’s up psychedelic stocks investors?!? Today marked atai Life Science’s (Nasdaq: atai) first-ever conference call, for Quarter 2, 2021. In the conference call, atai Life Sciences gave updates on their varying projects, ranging from attempting to treat depression, to cognitive impairment associated with schizophrenia. They also give insights on atai’s digital medicines division and answer investor’s questions at the end of the call.

This Peter Thiel-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 10+ different projects under their belt, atai is one of the most exciting companies to keep an eye on in the industry.

This conference call can help investors answer the questions: is atai stock a good investment? Will atai go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Check out our website: thepsychedelicinvestor.com

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

#atai #ataiLifeSciences #PsychedelicStocks

MindMed’s Financial Results & Business Update for Q2 2021 are out!
In this episode, we’ll discuss MindMed, ( MMED: NEO), (MNMD: NASDAQ), (MMQ: FRA), who recently announced their Q2 financials and gave a business update.
This was an important, transitional quarter for the company for several reasons.

First, and perhaps most significantly, during Q2, co-founder JR Rahn stepped down as CEO, being replaced by Robert Barrow, who was previously Chief Development Officer.

Second, in terms of progress in the mission to heal mental health, MindMed made several strides in this quarter, which we’ll discuss today.

Pertinent links:

MindMed’s CEO Jr Rahn Steps Down:
https://thepsychedelicinvestor.com/2021/06/09/mindmed-announces-chief-executive-officer-transition/

Project Angie Update:
https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/

MindMed’s Collaboration with NextStage Therapeutics:
https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/

MindMed’s Pharmacogenetic Study:
https://thepsychedelicinvestor.com/2021/05/26/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to-help-guide-personalized-dosing/

MMED’s Q2 Financial Results & Business Update:
https://thepsychedelicinvestor.com/2021/08/13/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-million-to-execute-on-diverse-clinical-pipeline/

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MindMedStock #MNMD

Mydecine (OTC: MYCOF, NEO: MYCO) is an aspiring psychedelics medicine company that aims to use psilocybin, the active ingredient in magic mushrooms, to treat smoking addiction and PTSD. First, they are using pure psilocybin called MYCO-001, but eventually, Mydecine wants to use a proprietary, shorter-lasting compound called MYCO-004.

While Mydecine probably isn’t considered as being in the top tier of psychedelic researchers (yet at least), they recently have teamed up with Johns Hopkins University and Dr. Matthew Johnson, an institution and individual widely considered to be leaders in the field. With this partnership, Mydecine may become a leader among the “shroom stocks”.

Specifically, Mydecine and Johns Hopkins are joining forces to run phase 2 and 3 clinical trials treating smoking addiction with psilocybin, though they may expand their partnership in the future.

Is Mydecine (MYCO:NEO) (MYCOF: OTC ) one of the best penny stocks of 2021? Can magic mushrooms treat smoking addiction? Watch the episode to find out!

Waht do you guys think about the Mydecine partnering up with Johns Hopkins University?

Links:
https://uploads-ssl.webflow.com/5ee12ebc38f9e96f52217dd1/610efbd58b2b1755e49eb55b_MYCO_Presentation_8.6.21-compressed.pdf

https://www.hopkinsmedicine.org/profiles/details/matthew-johnson

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MYDECINE #MYCO #JOHNSHOPKINS